HPV vaccination of immunocompromised hosts

    Thumbnail
    Download
    Citations
    Scopus
    Altmetric
    16
    Author
    Garland, SM; Brotherton, JML; Moscicki, AB; Kaufmann, AM; Stanley, M; Bhatla, N; Sankaranarayanan, R; de Sanjose, S; Palefsky, JM
    Date
    2017-12-01
    Source Title
    Papillomavirus Research
    Publisher
    ELSEVIER SCIENCE BV
    University of Melbourne Author/s
    Brotherton, Julia; Wark, Suzanne
    Affiliation
    Melbourne School of Population and Global Health
    Obstetrics and Gynaecology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Garland, S. M., Brotherton, J. M. L., Moscicki, A. B., Kaufmann, A. M., Stanley, M., Bhatla, N., Sankaranarayanan, R., de Sanjose, S. & Palefsky, J. M. (2017). HPV vaccination of immunocompromised hosts. PAPILLOMAVIRUS RESEARCH, 4, pp.35-38. https://doi.org/10.1016/j.pvr.2017.06.002.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/259652
    DOI
    10.1016/j.pvr.2017.06.002
    Abstract
    It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.

    Export Reference in RIS Format     

    Collections